Meeting
2014 Genitourinary Cancers Symposium
Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Antoine Angelergues
Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France
Antoine Angelergues , Denis Maillet , Aude Flechon , Mustafa Ozguroglu , Florence Mercier , Aline Guillot , Sylvestre Le Moulec , Gwenaelle Gravis , Philippe Beuzeboc , Christophe Massard , Thibault De La Motte Rouge , Nicolas Delanoy , Reza-Thierry Elaidi , Stephane Oudard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 282)
DOI
10.1200/jco.2014.32.4_suppl.282
Abstract #
282
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova
Poster
2017 ASCO Annual Meeting
Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Constance Thibault
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
First Author: Karim Fizazi
Poster
2020 Genitourinary Cancers Symposium
Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Julie Nicole Graff